194 related articles for article (PubMed ID: 35042460)
1. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
Couderc AL; Villani P; Berbis J; Nouguerède E; Rey D; Rossi D; Lechevallier É; Badinand D; Bastide C; Karsenty G; Boissier R; Amichi K; Muracciole X
BMC Cancer; 2022 Jan; 22(1):78. PubMed ID: 35042460
[TBL] [Abstract][Full Text] [Related]
2. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer.
Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
[TBL] [Abstract][Full Text] [Related]
3. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
[TBL] [Abstract][Full Text] [Related]
4. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
[TBL] [Abstract][Full Text] [Related]
5. Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study.
Legido-Gómez Ó; Rico-Marco S; Lorenzo-Sánchez MV; Navarro-Jiménez S; Tárraga-Honrubia MA; Martínez-Ruiz J; Giménez-Bachs JM; Donate-Moreno MJ; Díaz de Mera-Sánchez-Migallón I; Segura-Martín M; Alcantud-Córcoles R; Abizanda-Soler P; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2024 May; 48(4):304-310. PubMed ID: 38373481
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
Lee CE; Leslie WD; Lau YK
BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
8. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
Wallander M; Axelsson KF; Lundh D; Lorentzon M
Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
10. Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy.
Hanson ED; Sheaff AK; Sood S; Ma L; Francis JD; Goldberg AP; Hurley BF
J Gerontol A Biol Sci Med Sci; 2013 Apr; 68(4):490-8. PubMed ID: 23089339
[TBL] [Abstract][Full Text] [Related]
11. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
[TBL] [Abstract][Full Text] [Related]
12. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
Hershman DL; Unger JM; Wright JD; Ramsey S; Till C; Tangen CM; Barlow WE; Blanke C; Thompson IM; Hussain M
JAMA Oncol; 2016 Apr; 2(4):453-61. PubMed ID: 26720308
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
14. Moderators of resistance-based exercise programs' effect on sarcopenia-related measures in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis.
Lopez P; Newton RU; Taaffe DR; Winters-Stone K; Galvão DA; Buffart LM
J Geriatr Oncol; 2023 Jun; 14(5):101535. PubMed ID: 37229882
[TBL] [Abstract][Full Text] [Related]
15. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
16. Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.
Braga-Basaria M; Travison TG; Taplin ME; Lin A; Dufour AB; Habtemariam D; Nguyen PL; Kibel AS; Ravi P; Bearup R; Kackley H; Kafel H; Reid K; Storer T; Simonson DC; McDonnell M; Basaria S
PLoS One; 2023; 18(2):e0281508. PubMed ID: 36763576
[TBL] [Abstract][Full Text] [Related]
17. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
Mitsuzuka K; Arai Y
Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
[TBL] [Abstract][Full Text] [Related]
18. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
[TBL] [Abstract][Full Text] [Related]
19. Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation.
de Rooy C; Grossmann M; Zajac JD; Cheung AS
Endocr Relat Cancer; 2016 Jan; 23(1):R15-26. PubMed ID: 26432470
[TBL] [Abstract][Full Text] [Related]
20. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
